SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference... read more →
Sutro Achieves $10 Million Milestone Payment from Celgene Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 --... read more →
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN... read more →
Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif., Nov. 13, 2018 -- Sutro Biopharma,... read more →
Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief Financial Officer... read more →
A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018-- Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug Designation by the United States Food and... read more →
South San Francisco, California – September 26, 2018. Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform,... read more →
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief... read more →
Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and TheLeukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s... read more →
Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in... read more →